Good afternoon, everyone, and welcome to the TILT Holdings second quarterv earnings conference call and webcast. Today's call is being recorded for replay purposes. A replay of the audio webcast will be available in the investor section of the company's website approximately two hours after the completion of the webcast and will be archived for 30 days. I would now like to turn the conference call over to your host today, TILT's Head of Investor Relations and Corporate Communications, Lynn Ricci. Please go ahead. Thank you, Shamali. Good afternoon, everyone, and thank you for joining us. Earlier today, we issued our second quarter 2022 earnings press release. The press release, along with our quarterly report on Form 10-Q, is available on the U.S. Securities and Exchange Commission's website at www.sec.gov, on SEDAR at www.sedar.com, and our website at www.tiltholdings.com. Please note that during this afternoon's webcast, remarks made regarding future expectations, plans, and prospects for the company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, which we disclose in more detail in Amendment Number 2 to the Form 10 registration statement filed by TILT with the SEC and on SEDAR. We remind you that any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may update such forward-looking statements in the future, we specifically disclaim any obligation to do so except as otherwise required by law. As of today's call, we are presenting our financial results in accordance with the United States generally accepted accounting principles or GAAP. During the call, management will also discuss certain financial measures that are not calculated in accordance with GAAP. We generally refer to these as non-GAAP financial measures. These measures should not be considered in isolation or as a substitute for TILT's financial results prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to their nearest equivalent GAAP measure is available in our earnings press release that is an exhibit to our current report on Form 8-K that we filed with the SEC and SEDAR today and can be found in the investor relations section of our website. On today's call are TILT's CEO, Gary Santo, and CFO, Brad Hoch. Following ourv prepared remarks, we will open the call for a Q&A. During today's prepared remarks or during the Q&A session, we may offer non-GAAP metrics to provide greater insight into our business and/or our financial results. Please be advised that we may or may not continue to provide these additional metrics in the future. With that, I will now turn the call over to our CEO, Gary Santo. Thank you, Lynn, and good afternoon, everyone. The first half of 2022 was a challenging period for the cannabis industry as a whole, as the second quarter improvements that some thought would happen turned out to be muted at best, and the reduction in expectations for the remainder of the year by operators and analysts alike has been well documented over the past few weeks. As a company that does not look to compete with our operating peers, but to be their supplier of choice for plantware and hardware, it is only natural that we would be affected by their now revised expectations. Our hardware business, Jupiter Research, and the basis for the B2B strategy we undertook beginning in 2021, was most affected by this market softness, as after getting off to a fast start in April, we saw orders slow significantly with some of our largest customers who have historically placed sizable orders in the second quarter, still working through inventory ordered at the end of last year. Digging into the hardware side of the business a bit deeper, for the second time in three years, we are experiencing e significant change to how our customers are purchasing. While COVID-19 and supply chain issues required Jupiter to carry more stock on its balance sheet in order to accommodate historical purchase trends, customer order size remained large enough to justify the working capital required for such an approach. As we continue to work with our customers to refine their demand planning process, we are now seeing a shift towards smaller, more frequent orders, often placed just in time. That comes with its own working capital requirements, but Jupiter's long-standing excellence in supply chain and inventory management affords us the opportunity to pivot quickly. Over the next few months, we believe we have a strategy that will allow us to more cost-effectively manage the inventory necessary to support this change. Equally as important, as the largest distributor of CCELL hardware in the U.S., we spent the first half of this year working closely with Smoore International, the owner of the CCELL patent and our manufacturing partner, developing a new pricing structure for CCELL products that will allow Jupiter to provide premium hardware at much more affordable prices while stabilizing margins. I am pleased to report that this new pricing structure is going into effect as we speak, and we have already begun to take orders. As product ships and is delivered, we expect related results to start appearing in our fourth quarter financials. At the same time, our R&D team continues to develop new technology that is aligned with vape marketplace trends. We are actively developing products designed to meet the changing pace of formulations now in the market, reestablishing Jupiter as a leader in vaping hardware innovation. These new technologies remain on track for introduction before year-end. Our goal is to position Jupiter as the vendor of choice for hardware with a broad portfolio of offerings that cover a variety of form factors, quality, and price points, all backed by the superior quality control and assurance, customer service, and supply chain management that Jupiter is known for. As a result, we look to enter our busiest sales season with a better selection of products at more competitive prices and terms better suited to meet the demands of our customers. Turning to our plant touching operations, it is no secret that we operate in some of the most challenging markets in the U.S. Several data sources confirm that growth, while still present, has slowed in those markets. According to data provided by the Massachusetts Cannabis Control Commission, cannabis sales in Massachusetts increased approximately 6% from the first quarter to the second quarter. In Pennsylvania, BDSA Market Analytics reports that sales grew only about 1% over the same period. Ohio, however, remains a bright spot as their medical program continues to ramp, with sales growing 16% from Q1 to Q2. That said, our sequential growth outpaced all of these markets, significantly in the case of Ohio, and all on an organic basis. When TILT first announced its B2B strategy to the marketplace, it was with an eye towards the increasing competition in our markets and the associated price volatility we believed would occur by late 2022, early 2023. By focusing on wholesaling consumer packaged goods and establishing partnerships with brands that had authenticity, depth of brand architecture, and a proven ability to compete in highly competitive markets, we believed that we could become a one-stop shop for third-party products that operators previously had to curate on their own. As we have previously reported, the speed at which the market began to transition was quite a bit faster than anticipated, with the first signs showing in the second half of 2021, exacerbated in 2022 by what looks to be waning consumer demand in more mature markets, likely the result of macroeconomic factors that we have all been enduring since the start of the year. This is made for a difficult environment in which to be scaling a new business model, but early results continue to validate that model. As a result, we are doing what we can to accelerate the scaling of our operations while keeping TILT as lean as possible, continuing, as we have since 2019, to fund our business out of cash flow from operations. Speed does cost, though, and Brad will speak more about the impact of the increased headcount necessary to support our retail stores in Massachusetts and provide depth in our leadership team. However, the near-term margin impact is something we feel is necessary to achieve long-term success. During the second quarter, we signed two additional brands, Highsman and Black Buddha, bringing the total number of TILT brand partners to eight. To date, we have activated approximately 35% of the available SKUs across those six brands, six of those brands. By year-end, we expect to have all brands in market with 100% of their available SKUs, a sizable lift. As you might imagine, bringing brands into new markets can be challenging, especially medical markets such as Pennsylvania and Ohio, as packaging, formulation, and marketing requirements vary from market to market, resulting in both regulatory and supply chain issues. For most brand partners, that can prove challenging, but this is a core competency of TILT. While that may not eliminate those challenges, our team is at its best when identifying near-term, mid-term, and long-term solutions, allowing us to activate brands in new markets quicker than most. In fact, as our brand partners have worked through the activation process with us, not only is our team regularly recognized for providing a best-in-class experience, but we have received requests from these brands to provide advisory services and help manage their supply chains across all their markets, not just the ones where TILT has cannabis operations. I am pleased to report that at present, we are in negotiations with certain brands to provide those services nationwide and are excited to begin developing this emerging line of business. This ability to provide such a differentiated approach continues to draw interest among brands, with inbound inquiries from potential brand partners up almost 5x from what it was at the start of the year, keeping our corporate development pipeline strong. By the numbers, TILT experienced over 20% growth in our cannabis business on a year-over-year basis. Retail operations played a large role in that increase, as did our brand partner products, with bulk sales and TILT-branded products most affected by price volatility in the marketplace. That last point is a key one, as it was for precisely that reason that we launched our strategy last year. For example, per BDSA, quarter-over-quarter retail unit pricing was down approximately 7% in Massachusetts and 11% in Pennsylvania. As you might imagine, this has a trickle-down effect on wholesale pricing. While this is what we experienced on our bulk in TILT-branded products, pricing on our brand partner products was relatively flat. Remember that a core tenet of our strategy was to reduce volatility in wholesale pricing. While still a small sample size, those brand partner products that we have activated are doing exactly that. With Timeless now in market in Ohio and 1906 launching in that market later this week, Highsman and Black Buddha scheduled to launch in multiple markets by early fall, and many more SKUs to come across all brand partners and markets, in my opinion, we cannot activate and scale these brands fast enough. On the retail side of our business, where customer retention remains north of 70%, you may remember that part of our strategy includes using more of our available shelf space for brand partner and third-party products for some of our top customers. We have been targeting year-end 70-30 split, with 70% of our shelf space supporting non-TILT products, and I am pleased to report that we are ahead of schedule, having hit that split already in the second quarter. On the operational side of things, on prior calls, you heard our COO, Dana Arvidson, talk about the reboot of our gardens that took place at the start of the year in order to provide better strain diversity, increased potencies, and improved harvest yields. While such a reboot normally takes up to 18 months, our cultivation team has us on schedule to complete that reboot in 12, with new genetics planted in January being harvested and tested as we speak. In the span of eight months, we have increased available strain diversity by over 75%. While we are still in the midst of the pheno hunting process, the early results on the first harvests of these new genetics has been encouraging, with a 100% success rate on seeds planted in Massachusetts, a 70% success rate in Pennsylvania, and most strains having THC levels in the low to mid-20s right out of the gates. These numbers tend to improve as part of the pheno hunt process. As you might imagine, we are excited by these early results. Yields have also increased by three times in Massachusetts and seven times in Pennsylvania and continue to improve. We've also doubled production capacity in both markets, meaning we now have more clean, high-quality flower available and can turn that flower into more SKUs than we have ever produced before, all while leveraging the same assets. We expect the efficiencies gained from these improvements to become more apparent in the coming quarters. Before turning the call over to Brad, at a high level, I want to emphasize that going forward, as brand partner sales continue to become a greater portion of our total revenue mix, we believe that the strength and resilience of our strategy will become more evident in our consolidated financial results. That said, we need to be realistic about the current market environment discussed at the outset of my commentary, and whether this eventual shift in our revenue mix can be reasonably expected to occur in time to overtake the macro trends in 2022. While we continue to drive our brand partner sales through ongoing launches, management does not feel that the pace will be sufficient to completely overtake sector and macro headwinds. As a result, per our press release issued earlier today, we believe it prudent to revise our 2022 outlook to better reflect their impact, noting that we expect to continue generating positive EBITDA on a more modest revenue growth. Most importantly, we expect to remain cash flow positive and will continue to internally fund our business and growth objectives. With that, I will now turn the call over to Brad for more detail on our second quarter results. Thanks, Gary, and good afternoon, everyone. As a reminder, all results today are presented in U.S. dollars. Also, following the effectiveness of the company's Form 10 filed with the Securities and Exchange Commission, the company is now reporting in generally accepted accounting principles and not international financial reporting standards. Some previous quarter and year-end results may have been adjusted to align with U.S. GAAP reporting requirements. The IFRS to U.S. GAAP conversion required a tremendous amount of work, and I would like to thank our accounting team for their efforts in completing this strategic objective for the company. Jumping into results. Revenue in the second quarter of 2022 was $47.1 million, compared to $42.4 million in the first quarter. The sequential quarter increase was driven by 16% growth from our retail business. In the second quarter, we did not open any new retail dispensaries, but plan to open our Cambridge, Massachusetts medical dispensary at Inman Square within the next couple weeks. While showing solid sequential revenue growth, we did experience a 3% decrease compared to a year-ago quarter. The decrease was driven by lower sales volume and pricing for certain products in our hardware business, partially offset by more than 20% year-over-year growth in our cannabis operations. For our hardware business, we generated $34.8 million in revenue, compared to $31.1 million in Q1 and $38.5 million in the year-ago period. Regarding our cannabis operations, revenue in the second quarter was $12.2 million, compared to $11.3 million in the first quarter and $10 million in the year-ago period. Gross margin for the quarter was 23%, compared to 22% in Q1 and 27% in the second quarter of 2021. The year-over-year decline was primarily driven by pricing of certain product lines in our hardware business, as well as lower pricing at our wholesale cannabis operations. Gross margin in the second quarter was also negatively impacted due to product mix at our Massachusetts facility as we sold a higher percentage of low-margin trim product as we expedited moving older inventory out to get ready for additional brand partner SKUs as well as harvest of our new genetics. At the operating expense level, OpEx, less non-cash adjustments for stock compensation, depreciation and amortization, and impairment charges in the second quarter totaled $12.5 million, compared to $10.4 million in the first quarter of 2022. The sequential increase was driven by added headcount as well as one-time expenses related to refinancing activities, GAAP conversion, and legal fees. In comparison to the year-ago period of $9.3 million, the increase was primarily driven by $1.3 million of one-time expenses as well as increased headcount. Declining valuation trends within the industry and its impact on our market valuation was a triggering event for goodwill impairment evaluation within the quarter. As a result, our second quarter included an impairment of goodwill of $6.7 million related to the prior acquisition of Jupiter Research. This non-cash charge is added back for adjusted EBITDA purposes. Adjusted EBITDA in Q2 was $1.1 million, compared to $1.5 million in Q1 and $7.1 million in the year-ago quarter. This was the 10th consecutive quarter of positive adjusted EBITDA. Moving to the statement of cash flows. Cash provided by operations was $3.8 million compared to $2.7 million in the year ago period, driven primarily from a sell-through of inventory. Turning to the balance sheet, cash and cash equivalents, as well as restricted cash, was $34.7 million at June 30, 2022, compared to $7 million at year-end 2021, with the increase driven by $25.5 million of net proceeds from our sale leaseback in Massachusetts. In addition to the Taunton, Massachusetts facility sale leaseback transaction, we also signed a sale leaseback agreement relating to our Pennsylvania cultivation facility for proceeds of $15 million. The closing of this transaction is subject to completion of customary environmental reviews, which are well underway. Upon completion of the Pennsylvania sale leaseback transaction, we expect to have approximately $40 million in cash in escrow and available to repay our existing note holders. We continue to work with both our senior and junior note holders to finalize the future debt capital structure of the company, but the outcome will be an improved capital structure with extended maturities. As Gary outlined earlier, due to the evolving macroeconomic environment, inflationary impacts on consumer spending, lower cannabis wholesale pricing in Massachusetts and Pennsylvania, and adjusting for its customers' demand planning time into Jupiter, we are revising our outlook for 2022 and now expect revenue to range between $205 million-$210 million with adjusted EBITDA ranging between $10 million-$15 million. We also expect to remain cash flow positive and will continue to fund our business and growth objectives through internal cash generation. With that, I'll turn it over to Gary for closing comments. Thanks, Brad. Two Sundays ago, we hosted a five-hour event on Cape Cod introducing the Massachusetts marketplace to TILT's portfolio of brand partners, as well as reintroducing TILT and the full scope of our capabilities that we are able to offer. Each of our brand partners had the opportunity to present their origin story to an audience of over 180 bud tenders and buyers, and the audience soon understood why we had chosen to partner with each. As each brand spoke of their collaboration with TILT having been their most pain-free and successful launch to date, it was humbling for our team to see how well the audience received those comments as well. The conversations and relationships forged that night indicate that the market is still learning about TILT's differentiated approach while taking notice of how we can help them build their businesses. As we continue to go deeper in the markets we serve, we expect this story to spread. To that end, a quick update at the corporate level. A key part of our strategy is the ability to cross-sell our customers, linking the hardware and plantware sides of our business to create deeper, more sticky relationships that position TILT as a one-stop-shop for cannabis operators. This meant having to restructure our sales organization in order to bring our hardware, retail, and wholesale cannabis sales efforts under one centralized function. As we've mentioned in the past, attracting key talent to deepen our bench continues to be a priority for TILT, and in this case, we could not be more excited to have added Chris Kelly as our Senior Vice President of Revenue Growth, overseeing our newly centralized sales process. Chris comes to us from Trulieve, where he was an executive director of wholesale. He has also held leadership roles at Kellogg Company, Frito-Lay, and Diageo. Joining Chris is Vice President of Wholesale, Joe Wentzel, who joins us from Cure Solutions, where he was their vice president of revenue. As encouraging as it may be to attract this kind of talent from outside of our organization, I am most excited when we identify future stars from within. With our recent reorganization of Jupiter, we have promoted Patrick Mitchell to Senior Vice President of Inhalation and Accessories. Patrick has been with us for almost four years, learning from one of the best in the industry and Jupiter co-founder, Bob Crompton. When Bob indicated a desire to retire, it was only natural for Patrick to step into his role. While Bob will remain on as an advisor to Jupiter, I want to take this time to thank Bob for all of his contributions to the company over the years. From being one of two people with an idea, a garage in Phoenix, and one customer, to building a thriving business with over 700 customers producing more than $150 million in revenue each year, Bob has been at the center of it all. Together with the Chairman of our board, Mark Scatterday, he is a key part of the reason why Jupiter enjoys the reputation that it does. Under Patrick's leadership and Bob and Mark's ongoing guidance, we do not expect to miss a beat when it comes to hardware. In closing, as mentioned in my opening comments, the data is telling us that our strategy is working, but it is now a matter of scaling. Scaling in one of the most challenging economic environments in recent history is a demanding exercise. As I stated in our earnings release earlier today, we are committed to increasing our pace given market conditions, with even more brand partners and SKUs to launch across a larger operating footprint going forward. Together with a more competitive hardware portfolio, the launch of our medical dispensary in Cambridge, Massachusetts, later this month, and New York operations on the horizon, we will continue to scale our operations while generating positive cash flow to fund our business and growth objectives. With that, I will turn the call back over to Lynn. Thank you, Gary. Operator, we would now like to open the line for questions. Thank you. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your headset before pressing the star keys. One moment please while we poll for questions. Operator, while we're waiting for the polling of questions, we would like to address a question that did come in through the webcast. Gary, you said eight brand partners. What is the capacity for adding more brand partners? With that, what is the bandwidth for supporting all of those partners when it comes to new strains and production? Thanks, Lynn. It's a question we get all the time, actually. The reality is, you know, we're not looking to become a contract manufacturer with dozens upon dozens of brands that all provide the same service and tend to collide into one another. For us, it's about putting together a curated portfolio, so we are that one-stop shop. If we heard from the market loud and clear one thing, they like having complementary brands. When you look at the brands we sign, it really depends on what products they actually bring to market. If you think about 1906, for example, they have one or two lines. They're edibles, they're the drops, there's chocolates. We add them as a brand, but they only fill so many SKUs. That gives us the ability to add other SKUs for gummies or things like that. I don't know that we have a hard and fast number or limitation. I think it comes down to, again, how we're filling out our product grid, keeping the overlap as minimal as possible, and trying to create as wide a selection of products available and use our own house brand, Standard Farms, to fill in any gaps that might be unfulfilled in any of our markets. Operator, are there any other questions? It shows that we have no questions here, so therefore, I will turn it back to you, Lynn Ricci, for closing remarks. Okay, thank you. I'd like to thank everyone for joining our call today, and we look forward to updating you on our next call. Have a great day. This concludes today's conference, and you may disconnect your lines at this time. Thank you for-